Bio-Rad Laboratories, Inc. (BIO) Stock Score, Valuation & Financial Research
Bio-Rad Laboratories, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 35/100.
Quick answer for BIO
Bio-Rad Laboratories, Inc. currently has a Wall Street Score of 35/100. The stored market price is $369.32. Its financial score is 32/100. Its valuation score is 4/100. These figures are a research snapshot, not a buy or sell recommendation.
What Bio-Rad Laboratories, Inc. does
Bio-Rad Laboratories, Inc., established in 1952 and headquartered in Hercules, California, operates as a global provider of life science research and clinical diagnostic products. Its operations span across the United States, Canada, Europe, Asia, and Latin America. The company is organized into two primary divisions: Life Science and Clinical Diagnostics. The Life Science division is responsible for developing, manufacturing, and commercializing a diverse array of reagents, equipment, and laboratory instruments. These products are crucial for various research methodologies, biopharmaceutical manufacturing processes, and food quality testing. This segment focuses on specialized areas within the life sciences, including proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. Its clientele encompasses academic institutions (such as universities and medical sc
BIO financial snapshot
- Wall Street Score:
- 35/100
- Current price:
- $369.32
- Market capitalization:
- $9.94B
- Revenue:
- $2.59B
- Net income:
- $222.4M
- Free cash flow:
- $374.6M
- Cash:
- $517.0M
- Total debt:
- $1.20B
- EPS:
- 8.33
- P/E ratio:
- 44.3x
- Financial score:
- 32/100
- Valuation score:
- 4/100
- Revenue score:
- 8/100
What stands out
- Reported year-over-year revenue growth is +0.0%.
- Free cash flow is $374.6M, showing positive cash generation.
- The balance sheet shows $517.0M of cash versus $1.20B of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 4/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 32/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BIO
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.